Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression.

ABSTRACT:

Background

Immunotherapy, particularly the utilization of immune checkpoint inhibitors (ICIs), assumes a pivotal role in the comprehensive management of advanced lung cancer. There has been substantial deliberation regarding the appropriateness of extending ICIs treatment beyond the point of disease progression. This study delves into the potential benefits of sustained utilization of ICIs subsequent to disease progression in patients.

Methods

A retrospective analysis was conducted on a cohort of 248 patients diagnosed with advanced lung cancer who received treatment with ICIs. The study population comprised 99 patients in the treatment beyond progression (TBP) group and 42 patients in the non-treatment beyond progression (NTBP) group. Parameters including progression-free s

SUBMITTER: Chen C 

PROVIDER: S-EPMC10540839 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature